Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma (Q36496709)

14 August 2017

1 reference

title

Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma (English)

1 reference

14 August 2017

0 references

1 reference

2

David T Curiel

1 reference

14 August 2017

4

Gene P Siegal

1 reference

14 August 2017

Vladimir V Ternovoi

1

1 reference

PubMed ID

16751779

14 August 2017

Bruce F Smith

series ordinal

3

1 reference

14 August 2017

5 June 2006

1 reference

14 August 2017

Laboratory Investigation

1 reference

14 August 2017

86

1 reference

14 August 2017

8

1 reference

14 August 2017

748-766

1 reference

https://scigraph.springernature.com/pub.10.1038/labinvest.3700444

14 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Current treatment of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Principles of tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Cancer gene therapy: fringe or cutting edge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Adenovirus p53 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Why did p53 gene therapy fail in ovarian cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The cellular response to p53: the decision between life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Decision making by p53: life, death and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p53 function and dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Mdm2 promotes the rapid degradation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Regulation of p53 stability by Mdm2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The polyproline region of p53 is required to activate apoptosis but not growth arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The complexity of p53 modulation: emerging patterns from divergent signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The p53 pathway: positive and negative feedback loops

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

21 January 2018

p53: puzzle and paradigm

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Regulation of p53 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

MDM2--master regulator of the p53 tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The p53-mdm-2 autoregulatory feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Regulation of HDM2 activity by the ribosomal protein L11

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Cyclin G recruits PP2A to dephosphorylate Mdm2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Yin Yang 1 is a negative regulator of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The role of p53 in chemosensitivity and radiosensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Control of apoptosis by p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

To die or not to die: how does p53 decide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Live or let die: the cell's response to p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

PUMA, a novel proapoptotic gene, is induced by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

PUMA mediates the apoptotic response to p53 in colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

BID regulation by p53 contributes to chemosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Apaf-1 is a transcriptional target for E2F and p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p53RDL1 regulates p53-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Regulation of p53 downstream genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Regulation of PTEN transcription by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Stress-induced p53 runs a transcription-independent death program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Transcription-independent pro-apoptotic functions of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Complicating the complexity of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p53 has a direct apoptogenic role at the mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

PUMA couples the nuclear and cytoplasmic proapoptotic function of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The codon 72 polymorphic variants of p53 have markedly different apoptotic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

A novel cofactor for p300 that regulates the p53 response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

ASPP proteins specifically stimulate the apoptotic function of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The regulation of E2F by pRB-family proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Regulation of cell proliferation by the E2F transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

A revised picture of the E2F transcriptional network and RB function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Sibling rivalry in the E2F family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The E2F transcriptional network: old acquaintances with new faces

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

E2F1 pathways to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

ATM is a target for positive regulation by E2F-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

ASPP1 and ASPP2 are new transcriptional targets of E2F

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs-pRb2/p130 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The multiple roles of PTEN in tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

PTEN regulates Mdm2 expression through the P1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Cell and tissue responses to genotoxic stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Taking the study of cancer cell survival to a new dimension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Cellular survival: a play in three Akts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Regulation of cell death protease caspase-9 by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Suppression of apoptosis by basement membrane requires three-dimensional tissue organization and withdrawal from the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Death in the third dimension: apoptosis regulation and tissue architecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Introduction of wild-type p53 enhances thrombospondin-1 expression in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Interferons and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Interferons, interferon-like cytokines, and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Probing p53 biological functions through the use of genetically engineered mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p53 in embryonic development: maintaining a fine balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Immortal DNA strand cosegregation requires p53/IMPDH-dependent asymmetric self-renewal associated with adult stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p53 suppresses the self-renewal of adult neural stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Cytogenetics and molecular biology of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Dependence of induction of osteocalcin gene expression on the presence of wild-type p53 in a murine osteosarcoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Absence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The RUNX genes: gain or loss of function in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Runx2, a multifunctional transcription factor in skeletal development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Continuous expression of Cbfa1 in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfa1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Regulation of skeletal development by the Runx family of transcription factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The murine gene p27Kip1 is haplo-insufficient for tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Relationship of bone morphogenetic protein expression during osteoblast differentiation to wild type p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

P53 and beta-catenin activity during estrogen treatment of osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Microarray analysis reveals expression regulation of Wnt antagonists in differentiating osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Wnt signaling in osteoblasts and bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The Wnt signaling pathway in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Expression profiles of osteosarcoma that can predict response to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

A twist code determines the onset of osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

TWIST inactivation reduces CBFA1/RUNX2 expression and DNA binding to the osteocalcin promoter in osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Twist is a potential oncogene that inhibits apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Tumour stem cells and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Genetic mechanisms of tumor suppression by the human p53 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and chemotherapy (adriamycin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumour-suppressor transgenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Amplification of a gene encoding a p53-associated protein in human sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Expression of the coxsackievirus and adenovirus receptor in musculoskeletal tumors and mesenchymal tissues: efficacy of adenoviral gene therapy for osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Replicative adenoviruses for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The p400 complex is an essential E1A transformation target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone acetyltransferase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The 19-Kilodalton Adenovirus E1B Transforming Protein Inhibits Programmed Cell Death and Prevents Cytolysis by Tumor Necrosis Factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Genetically targeted adenovirus vector directed to CD40-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Transductional targeting of adenoviral cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Coxsackievirus and adenovirus receptor expression on primary osteosarcoma specimens and implications for gene therapy with recombinant adenoviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

High-level expression of the coxsackievirus and adenovirus receptor messenger RNA in osteosarcoma, Ewing's sarcoma, and benign neurogenic tumors among musculoskeletal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Reovirus sigma1 fiber incorporated into adenovirus serotype 5 enhances infectivity via a CAR-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Gene modification strategies to induce tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Tumor-stroma interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Molecular insights into prostate cancer progression: the missing link of tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Does the immune system see tumors as foreign or self?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Know thy neighbor: stromal cells can contribute oncogenic signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Spontaneously occurring tumors of companion animals as models for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

Productive replication of human adenovirus type 5 in canine cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

p63 and p73 are required for p53-dependent apoptosis in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Osteosarcoma Necrosis Following Chemotherapy: Innate Biology Versus Treatment-Specific

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Cell-cycle arrest versus cell death in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

mdm2 expression is induced by wild type p53 activity

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

p53 regulates the expression of the tumor suppressor gene maspin

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

An expression signature classifies chemotherapy-resistant pediatric osteosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

A human cell line selected for resistance to adenovirus infection has reduced levels of the virus receptor.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700444

7 January 2021

10.1038/LABINVEST.3700444

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16751779